Type II anti-CD20 antibody obinutuzumab outperforms rituximab in lupus trials, review finds
A new comparative review finds that the type II anti-CD20 antibody obinutuzumab succeeded in Phase 3 lupus trials where rituximab ...
Tag: REGENCY trial
POPULAR NEWS
-
Rumpelstiltskin Protein Guards Genome Boundaries in Fruit Flies
-
Carbon Monoxide Clears Slower Than Expected: Oxygen Therapy Half-Life Falters Over Time
-
Blood markers of neutrophil traps differ across four inflammatory skin diseases
-
Oyster Gene Marker for Herpesvirus Resistance Offers No Shield Against Bacterial Pathogen